ReviewBioengineering (Basel, Switzerland)2018
Therapeutic Use of Stem Cells for Myocardial Infarction.
Review in Bioengineering (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Five-year follow-up of intracoronary autologous cell therapy in acute myocardial infarction: the REGENERATE-AMI trial.ESC heart failure · 2022Trial
- Myrrhone exert cardioprotective effect against isoproterenol-induced myocardial injury in rats via alteration of NF-κB and Bax/Bcl-2/caspase-3 signaling.Acta cirurgica brasileira · 2025Article
- Advances in Nanoparticles in the Prevention and Treatment of Myocardial Infarction.Molecules (Basel, Switzerland) · 2024Review
- Pluripotent stem cell-derived committed cardiac progenitors remuscularize damaged ischemic hearts and improve their function in pigs.NPJ Regenerative medicine · 2023Article
- Human Bone Marrow-Derived Mesenchymal Stem Cell Applications in Neurodegenerative Disease Treatment and Integrated Omics Analysis for Successful Stem Cell Therapy.Bioengineering (Basel, Switzerland) · 2023Review
- Oogenesis in Women: From Molecular Regulatory Pathways and Maternal Age to Stem Cells.International journal of molecular sciences · 2023Review
- Cardioprotective Effect of Flibanserin against Isoproterenol-Induced Myocardial Infarction in Female Rats: Role of Cardiac 5-HT2A Receptor Gene/5-HT/CaPharmaceuticals (Basel, Switzerland) · 2023Article
- MicroRNAs as a Novel Player for Differentiation of Mesenchymal Stem Cells into Cardiomyocytes.Current stem cell research & therapy · 2023Review
- Greater angiogenic and immunoregulatory potency of bFGF and 5-aza-2'-deoxycytidine pre-treated menstrual blood stem cells in compare to bone marrow stem cells in rat model of myocardial infarction.BMC cardiovascular disorders · 2022Article
- Cardiac stem cells: Current knowledge and future prospects.World journal of stem cells · 2022Review
- Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases.Frontiers in pharmacology · 2022Review
- Intervention effects of traditional Chinese medicine on stem cell therapy of myocardial infarction.Frontiers in pharmacology · 2022Review
- Mesenchymal Stem Cell (MSCs) Therapy for Ischemic Heart Disease: A Promising Frontier.Global heart · 2022Review
- Genome-wide methylome pattern predictive network analysis reveal mesenchymal stem cell's propensity to undergo cardiovascular lineage.3 Biotech · 2022Article
- In vitro comparison of harvesting site effects on cardiac extracellular matrix hydrogels.Journal of biomedical materials research. Part A · 2021Article
- Cortical bone stem cells modify cardiac inflammation after myocardial infarction by inducing a novel macrophage phenotype.American journal of physiology. Heart and circulatory physiology · 2021Article
- Application of plasma polymerized pyrrole nanoparticles to prevent or reduce de-differentiation of adult rat ventricular cardiomyocytes.Journal of materials science. Materials in medicine · 2021Article
- What Means Fourth Industrial Revolution for Medicine.Maedica · 2021Article
- Article
- Consistent Long-Term Therapeutic Efficacy of Human Umbilical Cord Matrix-Derived Mesenchymal Stromal Cells After Myocardial Infarction Despite Individual Differences and Transient Engraftment.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction is a leading cause of morbidity and mortality worldwide. Although medical and surgical treatments can significantly improve patient outcomes, no treatment currently available is able to generate new contractile tissue or reverse ischemic myocardium. Driven by the recent/novel understanding that regenerative processes do exist in the myocardium-tissue previously thought not to possess regenerative properties-the use of stem cells has emerged as a promising therapeutic approach with high expectations. The literature describes the use of cells from various sources, categorizing them as either embryonic, induced pluripotent, or adult/tissue stem cells (mesenchymal, hematopoietic, skeletal myoblasts, cardiac stem cells). Many publications show the successful use of these cells to regenerate damaged myocardium in both animal and human models; however, more studies are needed to directly compare cells of various origins in efforts to draw conclusions on the ideal source. Although numerous challenges exist in this developing area of research and clinical practice, prospects are encouraging. The following aims to provide a concise review outlining the different types of stem cells used in patients after myocardial infarction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.